INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Grant or awardVerified data

Feinberg Peter reported IMRX

Director · Immuneering Corp · Immuneering Corp — Stock Option

Side
A
Value
—
Shares
7,888
Price
—
Executed
Jan 1, 2026
Disclosed
Jan 2, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Jan 1 executedJan 2, 2026 disclosed

IMRX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · IMRX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    29
    ZJ
    Zeskind Benjamin J.Director, PRESIDENT AND CEO
    IMRXImmuneering Corp
    Open-market purchase
    		BUY$11K
    2,400 sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    5
    FP
    Feinberg PeterDirector
    IMRXImmuneering Corp
    Grant or award
    		A—
    33.4K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    5
    SJ
    Schall Thomas J.Director
    IMRXImmuneering Corp
    Grant or award
    		A—
    33.4K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    9
    HD
    Hausman DianaDirector
    IMRXImmuneering Corp
    Grant or award
    		A—
    33.4K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CJ
    Carpenter Robert JDirector
    IMRXImmuneering Corp
    Grant or award
    		A—
    33.4K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    9
    KL
    Keating LaurieDirector
    IMRXImmuneering Corp
    Grant or award
    		A—
    33.4K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    62
    BE
    Brakewood Harold EugeneChief Business Officer
    IMRXImmuneering Corp
    Open-market purchase
    		BUY$25K
    5,250 sh
    		Jan 16, 2026Jan 21, 2026
    traded Jan 16, 2026
    		+5dSEC FORM 4

    Evidence

    61
    SJ
    Schall Thomas J.Director
    IMRXImmuneering Corp
    Open-market purchase
    		BUY$101K
    21.6K sh
    		Jan 15, 2026Jan 20, 2026
    traded Jan 15, 2026
    		+5dSEC FORM 4

    Evidence

    44
    HM
    Hall Brett MatthewCHIEF SCIENTIFIC OFFICER
    IMRXImmuneering Corp
    Open-market purchase
    		BUY$11K
    2,298 sh
    		Jan 15, 2026Jan 16, 2026
    traded Jan 15, 2026
    		+1dSEC FORM 4

    Evidence

    48
    NR
    Neufeld Leah RCHIEF PEOPLE OFFICER
    IMRXImmuneering Corp
    Open-market purchase
    		BUY$11K
    2,626 sh
    		Jan 13, 2026Jan 15, 2026
    traded Jan 13, 2026
    		+2dSEC FORM 4

    Evidence

    51
    FP
    Feinberg PeterDirector
    IMRXImmuneering Corp
    Open-market purchase
    		BUY$87K
    20.0K sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    KL
    Keating LaurieDirector
    IMRXImmuneering Corp
    Grant or award
    		A—
    7,888 sh
    		Jan 1, 2026Jan 2, 2026
    traded Jan 1, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001790340-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 1, 2026
    Published
    Jan 2, 2026
    Ingested by INSIDER
    Nov 5, 04:24 UTC
    Last re-read
    Nov 5, 04:24 UTC

    Extracted facts

    Filer
    Feinberg Peter
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Immuneering Corp — Stock Option
    Ticker
    IMRX
    Shares
    7,888
    Price per share
    $0
    Execution date (reported)
    Jan 1, 2026
    Owned after transaction
    7,888 shares
    Days from execution to publication
    1

    What this establishes

    Feinberg Peter filed this Form 4 reporting a grant or award of IMRX on Jan 1, 2026. It became public on Jan 2, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Feinberg Petercik:0001870076
    Issuer
    Immuneering Corpcik:0001790340

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.